Biotech M&A – 2023 Deals

Biotech M&A – 2023 Deals

Biotech M&A With a Quick Start in 2023!

Is There Any Chance to Beat 2022 Numbers ?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/04/2023ModernaMRNAOriCiro GenomicsPrivate- Japan$85M-Cynthetic biology and enzyme technologies
01/09/2023Chiesi Farmaceutici PrivateAmryt PharmaAMYT$1.25B$14.50$2.5 CVR total $225M
01/09/2023IPSEN - France IPSEYAlbireoALBO$952$42.00$10 CVR
01/09/2023Astra AZNCinCor PharmaCINC$1.3B$26.00$10 CVR
01/17/2023Shockwave MedicalSWAVNeovascNVCN$100M$27.25minimally invasive treatment of refractory angina.
01/19/2023Sun PharmaIndian Co.Concert PharmaceuticalsCNCE$576M$8.00$3.5 CVR
Oral JAK Inhibitor for the Treatment of Alopecia Areata
03/13/2023PfizerPFESeagenSGEN$43B$229Antibody-Drug Conjugates (ADCs)
03/13/2023SanofiSNYProvention BioPRVB$2.9B$25TZIELD disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
04/17/2023MerckMRKPrometheus BiosciencesRXDX$10.8B$200PRA023 a late-stage candidate for ulcerative colitis and Crohn’s disease
04/18/2023 GSKGSKBELLUS HealthBLU$2.00B$14.75P2X3 for Chronic Cough
04/25/2023Assertio HoldingsASRTSpectrum PharmaceuticalsSPPI$248M0.1783 ASRT shares per SPPI Share ($1.14/shr) CVR for potential of up to $1.34 per Share
04/27/2023Quest DiagnosticsDGXHaystack OncologyPrivate$300M + $150M-Liquid Biopsy
$150M achieving future performance milestones
04/30/2023 Astellas Pharma APLSIveric bioISEE$5.9B$40.00Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy
05/10/2023Swedish Orphan BiovitrumSOBICTI BioPharmaCTI$1.7B$9.10VONJO,- treatment of myelofibrosis
05/22/2023Ironwood PharmaceuticalsIRWDVectivBio Holding AGVECT$1B$17.00Synthetic GLP2 Analog in Ph3 for SBS-IF
06/12/2023NovartisNVSChinook TherapeuticsKDNY$3.2B$40 +$4 CVRdevelopment for IgAN, a rare, progressive chronic kidney disease
06/16/2023Coherus BiosciencesCHRSSurface OncologySURF$65M in CHRS shares$5.2831 CHRS share +CRVimmunotherapies in clinical development
06/20/2023Eli LillyLLYDICE TherapeuticsDICE$`2.4B$48oral IL-17 inhibitors
06/29/2023Eli LillyLLYSigilon TherapeuticsSGTX$34.6M$14.92 + CVR $111.64SIG-002, for the treatment of T1D
07/14/2023Eli LillyLLYVersanisPrivateup to $1.925 billionDown payment + milestones cardiometabolic diseases
07/17/2023NovartisNVSDTx PharmaPrivate$500M $500M Cash +MilestonessiRNA therapies for neuroscience
07/28/2023BiogenBIIBReata PharmaceuticalsRETA$7.3B$172.50SKYCLARYS® for Friedreich’s ataxia
08/10/2023Novo NordiskNVOInversago PharmaPrivate$1.075B-CB1 receptor-based therapies for obesity
09/26/2023Alfasigma - ItalyItalian Co.Intercept PharmaceuticalsICPT$794M$19Rare and Serious Liver Diseases

For M&A 2022 full table click here

Recent Press


Log In

JoinLost Password?